Incannex Healthcare Limited has appointed two principal investigators for its IND opening Phase 2/3 clinical trial, investigating IHL-42X for the treatment of obstructive sleep apnoea (OSA). The lead PIs recruited are Dr John D Hudson of FutureSearch Trials of Neurology, Austin, Texas and Dr Russell Rosenberg of Neurotrials Research Inc, Atlanta, Georgia. Site recruitment and selection in the US and other jurisdictions is an iterative process and Incannex plans to recruit approximately 45 sites across multiple jurisdictions for this pivotal trial.
Incannex Healthcare Limited is developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs such as OSA, traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders and pain among others. It has recruited two highly experienced lead principal investigators (PIs) for the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA.
The appointment of experienced lead principal investigators